XML 74 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 31, 2021
Feb. 28, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     $ 154,344,000 $ 98,382,000 $ 85,071,000
Revenue recognized $ 75,700,000   (95,789,000)    
Development Revenue          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     75,448,000 56,943,000 41,552,000
MRD Development Agreements          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     3,200,000    
Milestone revenue recognized     10,000,000.0 2,500,000 2,000,000.0
Revenue recognized     11,800,000 3,400,000 3,700,000
MRD Development Agreements | Maximum          
Disaggregation Of Revenue [Line Items]          
Additional milestone payment receivable 333,500,000   333,500,000    
MRD Development Agreements | Development Revenue          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     300,000    
Genentech Collaboration Agreement          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     62,000,000.0 $ 52,800,000 $ 35,100,000
Non-refundable upfront payments received   $ 300,000,000.0 $ 300,000,000.0    
Genentech Collaboration Agreement | Maximum          
Disaggregation Of Revenue [Line Items]          
Revenue recognition expected period     8 years    
Genentech Collaboration Agreement | Maximum | Regulatory Milestones          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments 75,000,000.0   $ 75,000,000.0    
Genentech Collaboration Agreement | Maximum | Development Milestones          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments 300,000,000.0   300,000,000.0    
Genentech Collaboration Agreement | Maximum | Commercial Milestones          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments 1,430,000,000.0   1,430,000,000.0    
Genentech Collaboration Agreement | Minimum          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments $ 1,800,000   $ 1,800,000    
Revenue recognition expected period     7 years